The average one-year price target for Microbot Medical (NasdaqCM:MBOT) has been revised to $7.65 / share. This is an increase of 12.50% from the prior estimate of $6.80 dated February 21, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $5.05 to a high of $12.60 / share. The average price target represents an increase of 191.98% from the latest reported closing price of $2.62 / share.
What is the Fund Sentiment?
There are 79 funds or institutions reporting positions in Microbot Medical. This is an decrease of 2 owner(s) or 2.47% in the last quarter. Average portfolio weight of all funds dedicated to MBOT is 0.00%, an increase of 96.34%. Total shares owned by institutions increased in the last three months by 21.20% to 12,883K shares. 
The put/call ratio of MBOT is 0.10, indicating a bullish outlook.
What are Other Shareholders Doing?
CIBC Private Wealth Group holds 1,480K shares representing 2.20% ownership of the company. In its prior filing, the firm reported owning 1,454K shares , representing an increase of 1.76%. The firm decreased its portfolio allocation in MBOT by 34.10% over the last quarter.
CIBC Bancorp USA holds 1,454K shares representing 2.17% ownership of the company.
Susquehanna International Group, Llp holds 1,245K shares representing 1.85% ownership of the company. In its prior filing, the firm reported owning 1,250K shares , representing a decrease of 0.39%. The firm decreased its portfolio allocation in MBOT by 34.16% over the last quarter.
Geode Capital Management holds 762K shares representing 1.13% ownership of the company. In its prior filing, the firm reported owning 493K shares , representing an increase of 35.25%. The firm decreased its portfolio allocation in MBOT by 2.05% over the last quarter.
DnB Asset Management AS holds 677K shares representing 1.01% ownership of the company. In its prior filing, the firm reported owning 244K shares , representing an increase of 64.04%. The firm increased its portfolio allocation in MBOT by 70.15% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
